LifeSci Capital Downgrades Larimar Therapeutics (LRMR) to Market Perform
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Price: $4.25 +4.68%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Join SI Premium – FREE
LifeSci Capital analyst Patrick Dolezal downgraded Larimar Therapeutics (NASDAQ: LRMR) from Outperform to Market Perform with a price target of $3.00.
For an analyst ratings summary and ratings history on Larimar Therapeutics click here. For more ratings news on Larimar Therapeutics click here.
Shares of Larimar Therapeutics closed at $4.01 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Temple & Webster Group Ltd (TPW:AU) to Sector Perform
- CIBC Downgrades Bank of Montreal (BMO:CN) (BMO) to Neutral
- CLSA Downgrades Tata Consultancy Services Ltd. (TCS:IN) to Hold (3)
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
